← Leaderboards
Sanjay J Mathew
Mount Sinai School Of Medicine Of Nyu
$5,866,298
Attributed
$6,086,298
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,086,298 · 15
VA$0 · 1
By mechanism
R01$3,283,448 · 3
R61$1,358,943 · 1
K23$802,664 · 1
R21$440,000 · 1
M01$201,243 · 9
I01$0 · 1
Top collaborators
- Nicholas Murphy2 shared
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseInvestigationResistancePharmaceutical PreparationsRandomizedPropertyAdultMental DepressionMajor Depressive DisorderKetamineAntidepressive AgentsMood DisordersDepressive SymptomsInnovationAdverse EffectsDoseResearch PersonnelAcuteSafetySamplingDesignDouble-Blind MethodInfusion ProceduresSite
Grant awards (33)
Gamma oscillations as a prognostic marker for ketamine therapy in treatment resistant depression$240,000
R21 · FY2025 · MH · contact PI
2/2 A brief automated neurocognitive training to enhance the real-world impact of ketamine's rapid antidepressant effect$876,888
R01 · FY2024 · MH · contact PI
Gamma oscillations as a prognostic marker for ketamine therapy in treatment resistant depression$200,000
R21 · FY2024 · MH · contact PI
Ketamine for Treatment Resistant Late-Life Depression$0
I01 · FY2020 · VA · contact PI
Ketamine for Treatment Resistant Late-Life Depression$0
I01 · FY2019 · VA · contact PI
NMDA receptor modulation for hyperarousal in PTSD$640,755
R61 · FY2018 · MH · contact PI
Ketamine for Treatment Resistant Late-Life Depression$0
I01 · FY2018 · VA · contact PI
Ketamine for Treatment Resistant Late-Life Depression$0
I01 · FY2017 · VA · contact PI
NMDA receptor modulation for hyperarousal in PTSD$718,188
R61 · FY2016 · MH · contact PI
Ketamine for Treatment Resistant Late-Life Depression$0
I01 · FY2016 · VA · contact PI
2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$223,106
R01 · FY2013 · MH · contact PI
Optimization of IV Ketamine for Treatment Resistant Major Depression$375,782
R01 · FY2012 · MH · contact PI
2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$232,403
R01 · FY2012 · MH · contact PI
2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$68,467
R01 · FY2012 · MH · contact PI
Optimization of IV Ketamine for Treatment Resistant Major Depression$287,644
R01 · FY2011 · MH · contact PI
2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$232,403
R01 · FY2011 · MH · contact PI
Optimization of IV Ketamine for Treatment Resistant Major Depression$306,969
R01 · FY2010 · MH · contact PI
2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$234,750
R01 · FY2010 · MH · contact PI
Optimization of IV Ketamine for Treatment Resistant Major Depression$445,036
R01 · FY2009 · MH · contact PI
CONTINUATION RILUZOLE IN PREVENTION OF RELAPSE FOLLOWING KETAMINE IN DEPRESSION$9,298
M01 · FY2009 · RR · contact PI
OPTIMIZATION OF IV KETAMINE FOR TREATMENT RESISTANT MAJOR DEPRESSION$244
M01 · FY2009 · RR · contact PI
PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER$161,175
K23 · FY2008 · MH · contact PI
CONTINUATION RILUZOLE IN PREVENTION OF RELAPSE FOLLOWING KETAMINE IN DEPRESSION$47,941
M01 · FY2008 · RR · contact PI
MRS NEUROMETABOLITES IN CHRONIC FATIGUE SYNDROME, GAD AND HEALTHY VOLUNTEERS$14,840
M01 · FY2008 · RR · contact PI
PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER$160,222
K23 · FY2007 · MH · contact PI
MRS NEUROMETABOLITES IN CHRONIC FATIGUE SYNDROME, GAD, AND HEALTHY VOLUNTEERS$34,041
M01 · FY2007 · RR · contact PI
CONTINUATION RILUZOLE IN PREVENTION OF RELAPSE FOLLOWING KETAMINE IN DEPRESSION$12,158
M01 · FY2007 · RR · contact PI
PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER$160,270
K23 · FY2006 · MH · contact PI
ADENOCINE RECEPTOR POLYMORPHISMS AND PHYSIOLOGIC RESPONSE TO CAFFEINE IN PD$51,474
M01 · FY2006 · RR · contact PI
MRS NEUROMETABOLITES IN CHRONIC FATIGUE SYNDROME, GENERALIZED ANXIETY DISORDER$20,376
M01 · FY2006 · RR · contact PI
PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER$159,316
K23 · FY2005 · MH
MRS NEUROMETABOLITES IN CHRONIC FATIGUE SYNDROME, GENERALIZED ANXIETY DISORDER$10,871
M01 · FY2005 · RR
PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER$161,681
K23 · FY2004 · MH